MacroGenics Inc. will study the ability of margetuximab to enhance the immune system's destruction of HER2-positive tumors in a Phase Ib/II clinical trial to evaluate the monoclonal antibody in combination with Merck & Co.'s PD-1 inhibitor Keytruda (pembrolizumab) in advanced gastric cancer.
Rockville, Maryland-based MacroGenics expects to begin patient enrollment for the trial, which will test the drug combination's safety in Phase...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

